Sponsored News: Wall Street has shown investors that the market is finicky in recent years. Although there are never any guarantees, it is possible to be certain that the market will always behave as you expect. “sure thing”Analysts agree that biotech companies still offer solid investment opportunities.
One company that is rising above its competitors is Endonovo Therapeutics (ENDV)Biotechnology company that develops bioelectronics-based products for regenerative medicine.
Analysts claim that this company is attractive because it is both a leader in the field of medical devices as well as in cell therapy.
Endonovo’s devices are based upon the Time-Varying Electromagnetic Field technology, which was originally developed by NASA. The technology works by sending electromagnetic pulses that deliver electrical stimulation to cells and the nervous system. These devices are non-invasive, non-implantable and can be used to treat and prevent vital organ failure. They reduce inflammation and cell death while encouraging regeneration.
Endonovo technology was shown to be a novel approach to treating acute inflammation in pre-clinical research. In contrast to other medical professionals who use implantable electrodes to treat patients, Endonovo is not using any implantable electrodes. The company is currently focusing its efforts on liver inflammation, which, if validated could transform medicine as inflammation is the root cause of all diseases.
The company also plans to apply for an orphan drug designation for its next generation, off-the shelf treatment for Graft-Versus Host (GvHD), using enhanced stem cells taken from the human umbilical chord.
Endonovo may be able to reach a $1 billion valuation if the FDA approves it for marketing its product.
GvHD is a rare condition where immune cells from donor bone marrow and cord blood transplants attack the recipient, leading to a failure of the transplant. This causes significant morbidity and death among recipients.
Endonovo has a different approach than other companies searching for a cure for GvHD. Endonovo doesn’t use genetic modification nor small molecule drugs to increase stem cell’s therapeutic properties. Yahoo Finance says that ENDV’s method can be applied to other types stem cells and is therefore easier to scale up and eventually manufacture.
Please visit this page for more information www.endonovo.com.
